Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and their imp...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2329240 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063694795374592 |
|---|---|
| author | Jennifer Soung Sonja Ständer Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold |
| author_facet | Jennifer Soung Sonja Ständer Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold |
| author_sort | Jennifer Soung |
| collection | DOAJ |
| description | Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and their impact on QoL measurements after treatment.Methods Data were analyzed from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) in patients with moderate-to-severe AD. QoL was evaluated using Dermatology Life Quality Index (DLQI) at Week 16 in patients (>16 years of age) who were itch responders/non-responders (defined as ≥4-point improvement in Pruritus Numeric Rating Scale) or Sleep-Loss Scale responders/non-responders (defined as ≥2-point improvement in itch interference on sleep).Results In ADvocate1 and ADvocate2, significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders.Conclusions Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2). |
| format | Article |
| id | doaj-art-c56bdf7a7a8a4644adf346f54f2ae8d3 |
| institution | DOAJ |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-c56bdf7a7a8a4644adf346f54f2ae8d32025-08-20T02:49:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2329240Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trialsJennifer Soung0Sonja Ständer1Jan Gutermuth2Ignasi Pau-Charles3Zach Dawson4Fan Emily Yang5Luna Sun6Evangeline Pierce7Hany Elmaraghy8Linda Stein-Gold9Southern California Dermatology, Inc, Santa Ana, CA, USAUniversity Hospital Westphalian Wilhems University, Munster, GermanyDepartment of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Jette, BelgiumAlmirall, Barcelona, SpainEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USAClinic for Dermatology, Henry Ford Health System, Detroit, MI, USABackground Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and their impact on QoL measurements after treatment.Methods Data were analyzed from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967) in patients with moderate-to-severe AD. QoL was evaluated using Dermatology Life Quality Index (DLQI) at Week 16 in patients (>16 years of age) who were itch responders/non-responders (defined as ≥4-point improvement in Pruritus Numeric Rating Scale) or Sleep-Loss Scale responders/non-responders (defined as ≥2-point improvement in itch interference on sleep).Results In ADvocate1 and ADvocate2, significantly greater proportions of itch responders had a clinically meaningful improvement in measures related to QoL (DLQI scores (0/1), ≤5 DLQI total score and ≥4-point DLQI improvement) compared to itch non-responders. In both studies, a significantly greater proportion of Sleep-Loss Scale responders, reported a DLQI score of (0/1), DLQI total score of ≤5 and DLQI improvement of ≥4 points compared to Sleep-Loss Scale non-responders.Conclusions Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).https://www.tandfonline.com/doi/10.1080/09546634.2024.2329240Atopic dermatitislebrikizumabquality of lifeitchsleep interference |
| spellingShingle | Jennifer Soung Sonja Ständer Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials Journal of Dermatological Treatment Atopic dermatitis lebrikizumab quality of life itch sleep interference |
| title | Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials |
| title_full | Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials |
| title_fullStr | Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials |
| title_full_unstemmed | Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials |
| title_short | Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials |
| title_sort | lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two phase 3 trials |
| topic | Atopic dermatitis lebrikizumab quality of life itch sleep interference |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2329240 |
| work_keys_str_mv | AT jennifersoung lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT sonjastander lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT jangutermuth lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT ignasipaucharles lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT zachdawson lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT fanemilyyang lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT lunasun lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT evangelinepierce lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT hanyelmaraghy lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials AT lindasteingold lebrikizumabmonotherapyimpactsonqualityoflifescoresthroughimproveditchandsleepinterferenceintwophase3trials |